Every 10-Q that Co-Diagnostics, Inc. (CODX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CODX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CODX filings page.
Co-Diagnostics, Inc. reported minimal revenue and persistent losses while highlighting a going concern risk. Revenue for the three and six months ended June 30, 2026 was $166,131 and $312,084, respectively. Net loss was $6.3 million for the quarter and $15.4 million year-to-date.
Cash and cash equivalents declined to $3.6 million from $11.9 million at December 31, 2025, driven by $15.0 million of operating cash outflows. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern over the next 12 months without additional capital.
The company continues heavy investment in its Co-Dx PCR platform, with $10.1 million in R&D expense in the first half of 2026. Liquidity was supplemented by an ATM equity program and a May 2026 private placement, providing $7.1 million of financing cash inflows in the first half, plus subsequent warrant exercises raising approximately $2.67 million.
Co-Diagnostics, Inc. reported a weak first quarter of 2026, with total revenue of $145,954 and a net loss of $9.14 million compared to a $7.53 million loss a year earlier. Cost of revenue exceeded sales, leading to a negative gross margin, while operating expenses rose to $9.16 million on higher research and development and legal and professional costs.
Cash and cash equivalents fell to $8.23 million at March 31, 2026, after using $7.85 million in operating cash in the quarter, partially offset by $4.33 million raised through an at-the-market stock program. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern over the next 12 months, reflecting dependence on new financing and future profitability.
Co-Diagnostics, Inc. (CODX) filed its Q3 2025 report, showing a sharp revenue decline and continued losses alongside new financing steps. Q3 revenue was $145,380 (vs. $641,141 a year ago) and net loss was $5.9 million (vs. $9.7 million). For the nine months, revenue was $358,567 (vs. $3.77 million) with a net loss of $21.2 million.
Operating expenses fell to $7.1 million in Q3 (from $10.6 million), reflecting lower legal, stock-based compensation, and personnel costs. Cash and cash equivalents were $11.44 million as of September 30, 2025.
The company raised capital during the period via an at-the-market program and a registered direct offering, and subsequently closed a $7.0 million registered direct deal and established a new ATM program for up to $10.0 million (with a prospectus supplement registering approximately $4.1 million). Management disclosed that substantial doubt exists about CODX’s ability to continue as a going concern over the next 12 months absent additional financing and improved operations.
Co-Diagnostics, Inc. (CODX) reported continued operating losses and heavy customer concentration alongside notable cash inflows in the first half of 2025. The company recorded a loss per share of $(0.23) and $(0.25) for the comparable three-month periods and $(0.47) and $(0.56) for the six-month comparatives, with weighted average basic shares around 33.1 million for the most recent quarter. Grant funding dropped to $0 for both the three- and six-month periods ended June 30, 2025, versus $2.5 million and $2.7 million in the prior-year periods. Accounts receivable net balances were $210,968 at June 30, 2025 and $132,570 at December 31, 2024, with two large customers representing a majority of receivables and three customers accounting for roughly 53% of product revenue in the quarter. Cash and liquidity improved: the company reported a $8.18 million net increase in cash and cash equivalents and received net proceeds of $1.02 million from an at-the-market equity program after selling 2,209,131 shares; maturities of marketable securities generated $31.51 million. Inventory totaled $1,084,627 with reserves recorded; the company recognized inventory reserve changes of $59,591 and $101,065 for the three- and six-month periods ended June 30, 2025. Lease obligations include operating lease long-term portion of $879,258 and present value of operating lease liabilities of $1,703,716. Nasdaq notified the company of a bid-price deficiency but CODX is eligible for an additional compliance period and may cure via a reverse split if needed.